Text Size

Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

This study has been completed.
Sponsor:
Information provided by:
Danish Procalcitonin Study Group
ClinicalTrials.gov Identifier:
NCT00144638
First received: September 1, 2005
Last updated: NA
Last verified: February 2005
History: No changes posted
  Purpose

Procalcitonin, a marker of infection has often been compared to clinical pictures as for instance "clinical sepsis". This has given som problems in the interpretation of these studies, because of the lack of good Gold Standards for "clinical sepsis. We have decided to investigate the development from day to day of Procalcitonin in the blood of intensive care patients, compared to the mortality.

Hypothesis: Procalcitonin increase after reaching a certain level predicts mortality in the Intensive Care Unit.


Condition
Sepsis - to Reduce Mortality in the Intensive Care Unit

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

Resource links provided by NLM:

MedlinePlus related topics: Sepsis
U.S. FDA Resources

Further study details as provided by Danish Procalcitonin Study Group:

Estimated Enrollment: 450
Study Start Date: January 2002
Estimated Study Completion Date: January 2003
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Admitted to the ICU 4131 of Rigshospitalet Copenhagen University Hospital in the year 2002

-

Exclusion Criteria:

Recent (< 3 months) liver transplantation

Expected admission < 24 h

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00144638

Locations
Denmark
Dept. 4131, Rigshospitalet, Cph University Hosp., DK
Copenhagen, Denmark, DK-2100
Sponsors and Collaborators
Danish Procalcitonin Study Group
Investigators
Principal Investigator: Lars Heslet, MD, MD.Sc. Dept. 4131, Rigshospitalet, Blegdamsvej 9, DK-2100
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00144638     History of Changes
Other Study ID Numbers: DPSG1
Study First Received: September 1, 2005
Last Updated: September 1, 2005
Health Authority: Denmark: National Board of Health

Additional relevant MeSH terms:
Critical Illness
Sepsis
Disease Attributes
Pathologic Processes
 Infection
Systemic Inflammatory Response Syndrome
Inflammation

ClinicalTrials.gov processed this record on May 22, 2013